Table 3. Ongoing studies using SBRT in oPC.

NCT	Title	Phase	Primary objective	Arms	Status
NCT04975516	Standard of Care Chemotherapy with or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer	II	PFS	Arm 1: SBRT once daily or every other day for 5 fractions and receive chemotherapy per standard of care	Recruiting
				Arm 2: chemotherapy per standard of care
NCT04498767	Stereotactic Body Radiotherapy in Patients with Rare Oligometastatic Cancers (OligoRARE)	III	OS	Arm 1: standard of care + palliative RT	Recruiting
				Arm 2: standard of care + SBRT
NCT03862911	Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer (SABR-COMET-3)	III	OS	Arm 1: palliative radiotherapy	Recruiting
				Arm 2: SABR 35 Gy in 5 fractions daily
NCT06593431	Extending Outcomes for Pancreas Cancer Patients with Nominal Oligometastatic Disease (EXPAND)	III	PFS	Arm 1: metastasis-directed therapy	Not yet recruiting
				Arm 2: systemic therapy alone

NCT, National Clinical Trial; oPC, oligometastatic pancreatic cancer; OS, overall survival; PFS, progression-free survival; RT, radiotherapy; SABR, stereotactic ablative radiotherapy; SBRT, stereotactic body radiation therapy.